ArticleJAMA oncology2020

Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.

Jill Furzer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.